Vaxart Raises $3.3M In Series A For Flu Vaccine

San Francisco-based Vaxart said Thursday that it has completed a $3.3M Series A financing. According to the firm, the round came from Quantum Technology Partners and Life Science Angels, which led the round, and also included Bay Partners and Sand Hill Angels. $600K of the funding came from a National Institutions of Health SBIR grant. According to Vaxart, it will use the capital to support late-stage preclinical testing and IND preparation for its vaccine for avian flu. More information »